

Imperial College London

## **Probiotics, Prebiotics, Oral Tolerance**




Robert Boyle MB ChB, PhD Clinical Senior Lecturer, Department of Paediatric Allergy Imperial College London, UK







#### Dendritic cells identify friend or foe



#### Dendritic cells identify friend or foe



#### Dendritic cells identify friend or foe



#### **Probiotics and Prebiotics for Allergic Disease**

**Probiotics** – live microorganisms which when administered in adequate amounts confer a health benefit on the host

**Prebiotic** – a selectively fermented ingredient that allows specific changes, in the composition and/or activity in the gastrointestinal microbiota, that confers benefits upon host well-being and health

Synbiotic – a combination of pro and prebiotic

#### **Health Benefits of Probiotics**

The precocious old age of ruminants... coincides with an extraordinary richness of the intestinal flora<sup>1</sup>



# SCIENTIST'S BAN ON SOUR-MILK GERM

Bacillus Bulgaricus Lauded by Metchnikoff Is of No Value, a Yale Man Says.

#### **Health Benefits of Probiotics**

- Treatment of infectious diarrhoea<sup>1</sup>
- Prevention of antibiotic associated diarrhoea<sup>2</sup>
- Prevention of flares of chronic pouchitis<sup>3</sup>
- Prevention of necrotising enterocolitis<sup>4</sup>

<sup>&</sup>lt;sup>1</sup> Allen Cochrane Database Syst Rev. 2003:CD003048

<sup>&</sup>lt;sup>2</sup> D'Souza BMJ 2002;324:1361

<sup>&</sup>lt;sup>3</sup> Gionchetti Gastroenterology 2000;119:305-9

<sup>&</sup>lt;sup>4</sup> Alfaleh Cochrane Database Syst Rev. 2008:CD005496

#### **Intestinal Microbes and Immune Development**


Normal mouse



Germ-free mouse



#### **Probiotic Safety – Fatal Bowel Ischaemia**



Besselink Lancet 2008; 371:651-9

#### **Intestinal Effects of Probiotic Bacteria**

TLR signalling by microbes — epithelial repair<sup>1</sup>

Inhibit NF-κB activation in intestinal epithelial cells<sup>2</sup>

Reduce intestinal inflammation/permeability in eczema<sup>3</sup>

<sup>1</sup>Cell 2004;118:229-41 <sup>2</sup>Nat Immunol 2004;5:104-12

<sup>3</sup>J Pediatr 2004;134:612-6

Imperial College London


#### **Systemic Immune Effects of Probiotics**

	Probiotic	Placebo	P value
Median CRP all infants	0.19	0.09	0.008
Median CRP infants with eczema	0.18	0.06	0.008

### **Probiotics for Eczema Prevention ?**

	Experim	mental Control		Risk Ratio		Risk Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI	
Abrahamsson 2007	34	95	32	93	10.7%	1.04 [0.70, 1.53]	<b>+</b>	
Huurre 2008	7	72	12	56	3.0%	0.45 [0.19, 1.08]	1	
Kalliomaki 2001	15	64	31	68	7.2%	0.51 [0.31, 0.86]	] <del></del>	
Kopp 2008	19	50	14	44	6.3%	1.19 [0.68, 2.09]	l <del> -</del>	
Kukkonen 2006	120	461	150	464	20.2%	0.81 [0.66, 0.99]	] =	
Niers 2009	23	50	30	48	11.3%	0.74 [0.51, 1.07]	] <del>-• </del>	
Rautava 2006	4	32	8	40	1.9%	0.63 [0.21, 1.89]	1 —	
Soh 2009	27	124	30	121	8.6%	0.88 [0.56, 1.39]	] -	
Taylor 2006	38	88	34	87	11.9%	1.10 [0.77, 1.58]	ı <del>+</del>	
West 2009	9	84	19	87	4.0%	0.49 [0.24, 1.02]	ı <del>-  </del>	
Wickens 2008a	21	144	20	75	6.6%	0.55 [0.32, 0.94]	]	
Wickens 2008b	37	152	20	75	8.3%	0.91 [0.57, 1.46]		
Total (95% CI)		1416		1258	100.0%	0.80 [0.69, 0.94]	•	
Total events	354		400					
Heterogeneity: Tau <sup>2</sup> = 0.02; Chi <sup>2</sup> = 15.79, df = 11 (P = 0.15); $I^2$ = 30%								
Test for overall effect: 2	Z= 2.71 (P	= 0.007	7)				0.01 0.1 1 10 100 Favours experimental Favours control	





# Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam

C. Flohr<sup>1,2</sup>, L. N. Tuyen<sup>3</sup>, R. J. Quinnell<sup>4</sup>, S. Lewis<sup>5</sup>, T. T. Minh<sup>3</sup>, J. Campbell<sup>2</sup>, C. Simmons<sup>2</sup>, G. Telford<sup>6</sup>, A. Brown<sup>6</sup>, T. T. Hien<sup>7</sup>, J. Farrar<sup>2</sup>, H. Williams<sup>8</sup>, D. I. Pritchard<sup>6</sup> and J. Britton<sup>5</sup>

Table 2. Effect of anti-helminthic treatment on study outcomes at 12 months' follow-up

	Anti-helminthic treatment, $N(\%)$	Placebo, N (%)	Size of effect*	P-value
Children infected with A. lumbricoides at baseline				
Total	52 (50.5)	51 (49.5)	-	-
Skin sensitization				
Any allergen	20 (38.5)	9 (17.6)	4.90 (1.48-16.19)	0.009
Rhinitis since start of treatment (questionnaire)	50 (6.7)	36 (4.9)	1.39 (0.89-2.15)	0.1
Flexural dermatitis since start of treatment (skin examination)	7 (0.9)	6 (0.8)	1.15 (0.39-3.45)	8.0
Skin sensitization				
Any allergen	251 (33.4)	207 (28.1)	1.31 (1.02, 1.67)	0.03


# **PREBIOTICS**

#### **Prebiotics**

- ➤ Major Constituent of Human Breast Milk
- ➤ Present at 10g/l
- ➤ Encourage proliferation of bifidobacteria in the infant large intestine
- ➤ May also have direct immune effects on developing infant GALT




# **Immune Modulation by Prebiotics**





Imperial College London


# **Immune Modulation by Carbohydrates**



#### **Prebiotics alter Intestinal Microbiota**








J Allergy Clin Immunol 2010;126:791-7


# PATCH – study design





## **PATCH**

#### **Participating sites**



#### **Conclusions**

- Microbial exposures may be important for preventing the onset of allergic sensitisation / disease
- Probiotics are relatively safe microbial exposures which may be helpful in this regard
- Prebiotics may reduce the risk of eczema in formula fed infants
- Treatment of helminth infestation increases skin prick test sensitivity